Mobile Marketing in the Pharmaceutical Industry: Benefits, Costs and Risks

QR Code

Mobile Marketing in the Pharmaceutical Industry: Benefits, Costs and Risks

The project will to look into the increasing trend for the mobile marketing worldwide and in particular the pharmaceutical industry. Afterwards will identify the list of the major benefits that can drive revenue for the pharmaceutical companies. Then, a costing analysis will be initiated to evaluate...

Full description

Bibliographic Details
Main Author:	Nofal, Hani
Format:	Dissertation (University of Nottingham only)
Language:	English
Published:	2011
Online Access:	https://eprints.nottingham.ac.uk/24888/

Similar Items

Exploring the use of cost-benefit analysis to compare pharmaceutical treatments for menorrhagia
by: Sanghera, Sabina, et al.
Published: (2015)

Pharmaceutical distribution networks in China: analysis of benefits and challenges of entering the Chinese market
by: Wegner, Jennifer
Published: (2015)

The impact of cost containment reforms to the Pharmaceutical Benefits Scheme (PBS) on prescribing volumes and expenditure in Australia: 1992-2011
by: Lee, Kah Seng
Published: (2014)

THE IMPACT OF COST CONTAINMENT REFORMS TO THE PHARMACEUTICAL BENEFITS SCHEME (PBS) ON PRESCRIBING VOLUMES AND EXPENDITURE IN AUSTRALIA: 1992 TO 2011
by: Lee, K., et al.
Published: (2014)

Risk of pharmaceuticals in water
by: Abdullah, Nur Imani
Published: (2017)

How Can E-Marketing Deliver Competitive Advantage to the Pfizer Injectables Brand in Europe?
by: Mohandas, Abhilasha, et al.
Published: (2011)

Pharmaceutical drug misuse: are industry of employment and occupation risk factors?
by: Brown, S., et al.
Published: (2015)

Are Australians Able to Access New medicines on the Pharmaceutical Benefits Scheme in a More or Less Timely Manner? An analysis of Pharmaceutical Benefits Advisory Committee Recommendations, 1999-2003
by: Wonder, M., et al.
Published: (2006)

Relationship marketing: Providing opportunities and benefits for the construction industry
by: Davis, Peter, et al.
Published: (2003)

International Strategies Of Danna Pharmaceutical Company In The Pharmaceutical Industry In Malaysia
by: Karbasi, Morteza
Published: (2011)

A case study on cost-benefit analysis for process industry equipment
by: Muhammad Syahril Ilham, Azhar
Published: (2025)

Costs and benefits of new apprenticeships
by: Dockery, Alfred Michael, et al.
Published: (2001)

The enigma of evaluation: Benefits, costs and risks of IT in Australian small-medium-sized enterprises
by: Love, Peter, et al.
Published: (2005)

Anthocyanidins and anthocyanins: colored pigments as food, pharmaceutical ingredients, and the potential health benefits
by: Hock, Eng Khoo, et al.
Published: (2017)

Applications for RFID in pharmaceutical industry
by: Potdar, M., et al.
Published: (2006)

Valuation of impacts in cost benefit analysis
by: S., Intan Syafinaz, et al.
Published: (2017)

CUSTOMER VALUE CREATION IN THE GENERICS PHARMACEUTICAL MARKET
by: Santos, Roberta
Published: (2010)

Benefits outweigh risks
by: Tang, Ashley
Published: (2022)

Data management challenges in pharmaceutical industry
by: Lubis, Muharman, et al.
Published: (2011)

Implementation of Bayesian methods in the pharmaceutical industry
by: Grieve, Andrew P.
Published: (1992)

Efficacy, Cost-Effectiveness, And Risk-Benefit Analysis Of Three Herbicides In Immature Oil Palm Plantation
by: Wibawa, Wahyu
Published: (2007)

Product Recalls and Stock Market Reaction: Empirical Evidence from the Pharmaceutical Industry in the UK And USA
by: Chieng, Corinne Lin Lin
Published: (2005)

Political connections and strategic choices of emerging market firms: Case study of Russia’s pharmaceutical industry
by: Klarin, Anton, et al.
Published: (2019)

Introduction to impact assessment and cost-benefit analysis
by: Khalid, Haniza
Published: (2018)

The costs and benefits of coordinating with a different group
by: Grout, Paul A., et al.
Published: (2015)

Blended Learning: more cost than benefit.
by: Tee, Lisa, et al.
Published: (2021)

A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: The Bosentan Patient Registry
by: Owen, A., et al.
Published: (2008)

Exploring predictors of e-marketing continuance intention in the Zimbabwean pharmaceutical industry during the COVID-19 pandemic
by: Aigbogun, Osaro, et al.
Published: (2023)

Listed companies in Malaysia and Singapore by market capitalization - a comparative risk, risk diversification benefits and performance analysis
by: Sea, Hui Ying
Published: (2019)

Benefits or costs? The effects of diversification with cross-industry knowledge on corporate value under crisis situation
by: Li, Zhi, et al.
Published: (2020)

The potential cost implications and benefits from building information modeling (BIM) in Malaysian construction industry
by: Chin, L., et al.
Published: (2018)

The Current and Future State of the Indian Pharmaceuticals Industry
by: Osman Kassam, Mohamed Zahir
Published: (2010)

The Current and Future State of China's Pharmaceutical Industry
by: Goh, Ming Tze
Published: (2010)

Applications of wireless sensor networks in pharmaceutical industry
by: Potdar, M., et al.
Published: (2009)

Evolution and governance of the biotechnology and pharmaceutical industry of China
by: Wang, K., et al.
Published: (2009)

Halal Computer Systems Validation Quality Assurance, Risk Assessment and Regulatory Compliance For The Pharmaceutical and Healthcare Industry
by: Raja Ikram, Raja Rina, et al.
Published: (2012)

A Study on the risk-return characteristics and the diversification benefit of the Hedge Fund industry
by: Bagaria, Neha
Published: (2007)

Cost-benefit analysis of kenaf as biomaterial for automotive components
by: Ong, Chu Lee
Published: (2015)

Benefit cost analysis of two proposed highway projects
by: Wong, Catherine
Published: (1965)

Cost-benefit analysis of organisational migration to IPv6
by: Yee, Hong Weng
Published: (2012)